We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Ret5.5
Retatrutide Research
Too few graded studies
52 peer-reviewed studies
What the evidence says
Too few graded studies
Retatrutide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2022–2026.
Based on 52 studies · 12 meta-analyses · 11 RCTs
Confidence
High confidence
By outcome
Weight managementIn the 48-week phase-2 obesity trial the 12 mg dose produced ~24.2% mean weight loss; phase-3 confirmation still pending · Progressive over 24-48 weeks
Too few graded studies40 studies
Glucose & glycemic controlDose-dependent HbA1c reductions in type 2 diabetes (top doses ~-2.0%, outperforming dulaglutide) · By 24-36 weeks · Combined large weight loss, liver-fat reduction and glycemic control point to broad metabolic benefit (phase-2) · By 24-48 weeks
Too few graded studies28 studies
Safety profile
Too few graded studies12 studies
Liver fat & MASLDIn a phase-2a MASLD substudy, liver fat fell ~81-82% at 8/12 mg; promising but early, no histology/outcome data · By 24 weeks
Mostly mechanism / observational5 studies
Active research area
52 studies in the last 5 years · Latest meta-analysis: 2026
20222026
1Meta-Analysis2025
Yin Y, Zhang M, Cao Q, Lin L, Lu J, Bi Y · J Diabetes (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: A broader understanding of these pleiotropic effects is essential to inform personalised obesity management and optimise long-term clinical outcomes.
Savas M, Kuckuck S, Boon MR, van Rossum EFC. · The lancet. Diabetes & endocrinology (2026)
Overall, GLP-1-based and multiagonist therapies show beneficial effects across these comorbid conditions.
While many benefits of obesity medications are mediated by weight loss, accumulating evidence indicates important weight loss-independent effects, particularly with GLP-1 receptor agonist-based therapies.
A broader understanding of these pleiotropic effects is essential to inform personalised obesity management and optimise long-term clinical outcomes.
In plain English: GLP-1 RAs carry a slightly increased risk of pancreatitis, which is not significant when stratified by background medication use.
Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B, Kou M, Muttalib Z, Alam A, Frezza E. · Endocrinology, diabetes & metabolism (2025)
Meta-analysis showed a significantly increased risk of pancreatitis (RR: 1.44, 95% CI 1.09-1.89, p = 0.009), but not when stratified by background medications (RR: 1.28, 95% CI 0.87-1.87) and without background medications (RR: 1.37, 95% CI 0.91-2.05).
Pancreatic cancer and GLP-1 RA use showed no significant association (RR: 1.30, 95% CI 0.86-1.97).
However, a significant increase was found with background medications (RR: 1.85, 95% CI 1.05-3.26, p = 0.03), but not without (RR: 0.81, 95% CI 0.43-1.55).
In plain English: GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH.
Wang Y, Zhou Y, Wang Z, Ni Y, Prud'homme GJ, Wang Q. · The Journal of clinical endocrinology and metabolism (2025)
Mean differences and risk ratios with 95% confidence intervals were pooled using a random-effect model.
Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%, with retatrutide displaying the most obvious treatment effects.
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation but nonsignificantly improved fibrosis, with the evidence for tirzepatide more robust than that for semaglutide and liraglutide.
In plain English: In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.
Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C. · The lancet. Diabetes & endocrinology (2025)
This substudy assessed percent change from baseline to week 36 in total body fat mass versus placebo and dulaglutide.
Eligible participants were adults aged 18-75 years with type 2 diabetes, HbA 1c of 7·0-10·5%, stable bodyweight, and BMI of 25-50 kg/m 2 .
The prespecified primary substudy endpoint was percent change from baseline to week 36 in total fat mass, as measured by dual-energy X-ray absorptiometry (DXA).
In plain English: GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.
Zhang S, Yu B, Xu J, Jin S, Li Y, Bing H, Li J, Ma X, Zhang X, Zhao L. · Diabetes technology & therapeutics (2025)
In terms of Δ body weight, retatrutide (12 mg qw) was the most effective treatment (mean difference = -26.56% [95% confidence interval: -43.89% to -3.01%]).
Tirzepatide (15 mg qw) demonstrated good weight loss ability in all three ΔBW models, ΔBW-NDOOG (-22.76% [-26.45% to -18.50%]), ΔBW-T2DCG (-11.09% [-12.39% to -9.44%])), and ΔBW-T2DAG (-4.97% [-5.84% to -4.12%]).
GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.
In plain English: Incretin-based therapy led to a modest but clinically meaningful BP reduction and lower all-cause mortality in adults with overweight or obesity, without excess in hypoglycaemia or pancreatitis episodes.
Basile C et al. · European journal of preventive cardiology (2026)
Random effects meta-analyses generated mean differences (MDs) or risk ratios (RRs) along with 95% confidence intervals (CIs).
GLP1-RAs reduced SBP by 3.4 mmHg (95% CI 2.8-4.0) and DBP by 0.9 mmHg (95% CI 0.5-1.2).
All-cause mortality was reduced by 18% (RR 0.82, 95% CI 0.76-0.90).
In plain English: This perspective underscores the urgent need for scientific engagement, equity considerations, and policy preparedness, positioning retatrutide as a watershed in obesity treatment and a blueprint for future poly-agonist therapies.
Ganamurali N, Sabarathinam S. · Clinical pharmacology in drug development (2026)
Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, represents a transformative advance in obesity pharmacotherapy.
Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease.
Retatrutide exemplifies rational multi-agonist peptide engineering and signals a paradigm shift in systems pharmacology.
In plain English: Expert opinion These promising effects on glycemic control, weight loss, and emerging pleiotropic actions merit further investigation.
Panou T, Gouveri E, Popovic DS, Papanas N. · Expert review of clinical pharmacology (2026)
In subjects with type 2 diabetes mellitus (T2DM), decreased glycated hemoglobin (HbA 1c ) by up to 2.16% and decreased fasting glucose by up to 69.1 mg/dL have been seen.
Weight loss up to 16.94% was observed in subjects with T2DM.
Subjects with overweight or obesity experienced a greater weight loss by up to 26.56% (24.15 kg).
In plain English: Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.
Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM. · Proceedings (Baylor University. Medical Center) (2025)
No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24).
Conclusion Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.
However, additional large and long-term trials are required to establish these results.
In plain English: This review provides an updated synthesis of therapeutic developments and outlines priorities for future research, regulatory policy, and equitable global integration as incretin-based therapies have evolved into a versatile class addressing glycaemic control, weight loss, and cardio-metabolic risk.
Gupta M et al. · The Indian journal of medical research (2026)
Dual GIP/GLP-1 agonist tirzepatide and triple agonist retatrutide have shown unprecedented efficacy, with up to 24% body weight reduction and improvement in hepatic and inflammatory markers.
Despite promising outcomes, challenges persist in terms of cost, accessibility, and the underrepresentation of low- and middle-income countries in major trials.
Pharmacogenomic variability may also influence therapeutic response.